Role of the CHADS$_2$ Score in the Evaluation of Carotid Atherosclerosis in Patients with Atrial Fibrillation Undergoing Carotid Artery Ultrasonography

Le-yu Lin,1,2 Lian-wei Yang,1,3 Yuan-yuan Shang,1 Yi-hui Li,1,4 Ming Zhong,1 Wei Zhang,1 and Hui Zhu

1The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health and the State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Department of Cardiology, Qilu Hospital of Shandong University, Jinan, Shandong, China
2Department of Emergency, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
3Department of Cardiology Group Two, Weihai Municipal Hospital, Weihai, Shandong, China
4Department of Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, Shandong, China

Correspondence should be addressed to Hui Zhu; zhuhui196@163.com

Received 5 May 2018; Revised 12 July 2018; Accepted 8 August 2018; Published 19 August 2018

Academic Editor: Andrea I. Guaricci

Copyright © 2018 Le-yu Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. This study investigated the characteristics of carotid atherosclerosis in patients with atrial fibrillation (AF) and determined the feasibility and significance of the CHADS$_2$ score in predicting the degree of carotid atherosclerosis. Methods. Consecutive patients (n = 109) with nonvalvular AF were registered and classified into two groups, the paroxysmal AF group (n = 59) and persistent AF group (n = 50). Fifty healthy patients, matched by sex and age, were considered the control group. All patients were examined using carotid ultrasound and velocity vector imaging (VVI). Results. Compared with the control group, the mean intimal-medial thickness in the paroxysmal AF group (0.56 ± 0.11 versus 0.61 ± 0.10, respectively, $P < 0.05$) and the persistent AF group (0.56 ± 0.11 versus 0.64 ± 0.13, respectively, $P < 0.001$) was significantly increased. The plaque index (PI) in the persistent AF group was significantly higher than that observed in the paroxysmal AF group (1.05 ± 1.33 versus 1.42 ± 1.47, respectively, $P < 0.001$). Regarding the VVI indices, those reflecting the long-axis longitudinal motion function of carotid arteries were significantly decreased in both AF groups. Compared with the control group, a significantly lower total longitudinal displacement (tLoD) index was observed in the persistent AF group (0.73 ± 0.66 versus 0.31 ± 0.23, respectively, $P < 0.0001$) and the paroxysmal AF group (0.73 ± 0.66 versus 0.34 ± 0.17, $P < 0.0001$). The CHADS$_2$ score was related to indicators reflecting the structure and function of the carotid artery. Conclusions. Carotid arterial structure and function were significantly altered in patients with AF. The degree of carotid atherosclerosis depended on the duration of AF. The CHADS$_2$ score may be useful as a predictor of the extent of carotid atherosclerosis in patients with AF.

1. Introduction

Atrial fibrillation (AF) is one of the most common arrhythmias observed in clinical practice. Thromboembolic complications are the most serious consequences of AF [1]. Previous studies [2] documented that the main source of emboli in ischemic stroke with AF was left atrial thrombus. However, the major underlying causes of nonvalvular AF (hypertension, diabetes, coronary heart disease, and advanced age) have also been associated with a high risk for the development of atherosclerotic lesions. AF and atherosclerosis may mutually influence the development of each other [3, 4]. AF combined with carotid atherosclerotic stenosis may markedly increase the risk of recurrent ischemic stroke [5].

The CHADS$_2$ (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and prior stroke) score is used to evaluate the risk of stroke in patients with AF [6]. It has a strong predictive effect regarding the development of cardiac adverse events of left atrial origin in patients with AF [7, 8]. However, its role in predicting
embolism of carotid plaque origin has not been determined.

Doppler ultrasound is able to evaluate the structure and function of the carotid artery intuitively to reflect related indices of atherosclerosis. Velocity vector imaging (VVI) is a novel ultrasound method, based on multiple M-mode evaluations and speckle-tracking technique [9, 10]. VVI allows the simultaneous evaluation of longitudinal and radial velocity, strain, strain rate, and displacement of the common carotid artery (CCA) wall motion [10]. The combination of VVI technology and Doppler ultrasound may evaluate the elasticity of the carotid vascular wall more comprehensively.

In the present study, Doppler ultrasound and VVI were used to explore the characteristics of carotid atherosclerosis in patients with AF and determine the feasibility and significance of the CHADS2 score in predicting the degree of carotid atherosclerosis.

2. Methods

2.1. Study Design. A total of 109 patients with nonvalvular AF fulfilling the inclusion criteria were enrolled in the study between September 2011 and May 2012. Of those, 59 patients had paroxysmal AF (22 males and 37 females, mean age: 58.32 ± 10.18 years [range: 30–75]) and the remaining 50 had persistent AF (18 males and 32 females, mean age: 59.30 ± 8.94 years [range: 25–78]). Nonvalvular AF was defined as AF in the absence of rheumatic mitral valve disease, a prosthetic heart valve, or mitral valve repair [11, 12]. AF which resolved spontaneously was designated as paroxysmal. Sustained AF which resolved through pharmacological intervention or electrical cardioversion was designated as persistent [12].

For the control group, 50 healthy patients (22 males and 28 females, mean age: 55.98 ± 7.19 years [range: 38–76]), matched by sex and age, were recruited from hospital staff and volunteers.

All patients were examined using electrocardiography (ECG) and 24-hour dynamic electrocardiography and echocardiography. Data including medical history, history of thromboembolism, history of drug use, and history of smoking/drinking were collected in detail.

2.2. Biochemical Assessments. All samples were collected following a 14-hour overnight fast and centrifuged within 30 minutes of collection. The levels of total serum cholesterol, low-density lipoprotein (LDL) cholesterol, triglyceride, high-density lipoprotein (HDL) cholesterol, and fasting blood glucose were analyzed from blood samples and measured using routine laboratory methods.

The study was conducted in accordance with the guidelines of the Declaration of Helsinki on biomedical research involving human subjects. Written informed consent was provided by all patients, and the study protocol was approved by the institutional ethics committee.

2.3. Acquisition of Carotid Ultrasound Index. The carotid ultrasound index of the study population was acquired using a Siemens Sequoia™ 512 color Doppler ultrasonic diagnostic apparatus. The probe frequency was 8.0–14.0 MHz. B-mode real-time ultrasound was performed to evaluate the wall thickness of the carotid artery. An expert sonographer, blinded to the data of the patients, performed the sonographic evaluations. Patients were examined in the supine position, as previously reported [13–15].

The probe was deployed approximately 1.5 cm proximally to the bifurcation of the CCA, and the longitudinal plane was used to visualize the maximum diameter of the lumen. Five segments were identified and measured in the anterior and posterior planes. At each of these sites the intimal-medial thickness (IMT) was determined, defined as the distance between the echogenic line representing the intimal blood interface and the outer echogenic line representing the adventitial junction. The maximum IMT value was determined as the mean IMT of the left and right arteries and was used for analysis.

During ultrasound assessments, the blood flow velocity in the carotid artery, arterial compliance, carotid stiffness index, resistance index, and other related indicators were measured. All detected plaques were counted, and their characteristics (fibrous, calcified or soft, presence, or absence of stenosis) were determined. The degree of plaque was graded on a scale from 0 to 3 (0 = no observable plaque; 1 = one small plaque [<30% of vessel diameter]; 2 = one medium plaque [30%–50% of vessel diameter] or multiple small plaques; and 3 = one large plaque [50% of vessel diameter] or multiple plaques with at least one medium plaque) [16].

2.4. Velocity Vector Imaging Acquisition and Analysis. All VVI-measurements were performed offline at a workstation by two independent observers. The VVI software (syngo® US workplace) was used to determine vessel wall velocity, strain, strain rate, and displacement of both the near and far wall of the CCA. Using the VVI mode of the device, the frame rate was adjusted to >60 frames/s. The transverse distal CCA approximately 1-cm inferior to the carotid bulb and free of plaque was used for analysis. Five guiding points were equally distributed (0.25-cm apart) within a 1-cm segment on the near wall and far walls; i.e., a total of 10 measuring points were used [17]. Dynamic images of three consecutive cardiac cycles were acquired and stored. The segmental values of the VVI parameters from both sides of the CCA were measured independently and averaged [17–19]. The total longitudinal displacement (tLoD) during a cardiac cycle was calculated as the sum of absolute values of the maximal systolic and maximal diastolic displacements. Patients with paroxysmal atrial fibrillation undergo carotid ultrasound during the onset of atrial fibrillation.

2.5. Statistical Analysis. All analyses were performed using the SPSS software (version 18.0, IBM Crop., Armonk, USA). Descriptive statistics were used to summarize the data. Categorical variables were expressed as percentages, while continuous variables were expressed as mean ± standard deviation. Differences between groups distributed variables were evaluated using one-way analysis of variance. Student’s t-test was used to compare parameters between two groups. Correlation coefficients and their significance were calculated using Spearman’s test. Possible predictors, identified through
### Table 1: Baseline clinical characteristics.

|                             | Control group (n = 50) | Paroxysmal AF group (n = 59) | Persistent AF group (n = 50) |
|-----------------------------|------------------------|------------------------------|-----------------------------|
| Age (years)                 | 55.98 ± 7.19           | 58.32 ± 10.18                | 59.30 ± 8.94                |
| SBP (mmHg)                  | 122.74 ± 13.34         | 135.19 ± 19.41***            | 137.48 ± 18.32***           |
| DBP (mmHg)                  | 81.1 ± 61.29           | 79.51 ± 13.81                | 83.90 ± 12.44               |
| Heart rate min⁻¹            | 66.60 ± 11.72          | 71.68 ± 24.20                | 88.58 ± 20.99***            |
| Body mass index (kg/m²)     | 24.76 ± 4.53           | 26.18 ± 3.52                 | 26.12 ± 3.67                |
| Waist-hip ratio             | 0.87 ± 0.06            | 0.89 ± 0.06*                 | 0.91 ± 0.05***              |
| Fasting glucose (mmol/L)    | 5.42 ± 0.79            | 5.67 ± 2.04                  | 5.48 ± 1.06                 |
| Cholesterol (mmol/L)        | 5.02 ± 0.99            | 4.77 ± 0.95                  | 4.79 ± 1.40                 |
| HDL cholesterol (mmol/L)    | 1.35 ± 0.27            | 1.29 ± 0.30                  | 1.23 ± 0.30                 |
| LDL cholesterol (mmol/L)    | 2.65 ± 0.62            | 2.74 ± 0.72                  | 2.76 ± 1.02                 |
| Triglycerides (mmol/L)      | 1.50 ± 0.91            | 1.50 ± 0.74                  | 1.73 ± 1.19                 |
| Male (%)                    | 22 (44%)               | 37 (62%)                     | 32 (64%)                    |
| Smoking history (%)         | 17 (33%)               | 23 (39%)                     | 23 (46%)*                   |
| Drinking history (%)        | 15 (29%)               | 27 (46%)**                   | 27 (53%)**                  |
| Hypertension (%)            | 8 (16%)                | 36 (62%)**                   | 29 (57%)                    |
| Diabetes mellitus (%)       | 24 (4%)                | 12 (20%)*                    | 8 (16%)                     |
| CAD (%)                     | 0                      | 21 (36%)**                   | 21 (41%)**                  |
| Prior Stroke (%)            | 0                      | 3 (5%)                       | 13 (26%)***                 |
| Statins (%)                 | 0                      | 13 (22%)*                    | 13 (26%)**                  |
| Beta-blockers (%)           | 1 (2%)                 | 36 (61%)**                   | 32 (64%)**                  |
| ACEI (%)                    | 0                      | 22 (37%)**                   | 12 (23%)**                  |
| ARB (%)                     | 0                      | 14 (24%)**                   | 20 (39%)**                  |
| Anticoagulants (%)          | 1 (2%)                 | 24 (41%)**                   | 19 (37%)**                  |
| Aspirin (%)                 | 2 (4%)                 | 35 (60%)**                   | 36 (71%)**                  |
| CHADS₂ score               |                         |                             |                             |
| 0 (%)                       | 38 (76%)               | 20 (33.9%)                   | 17 (34%)                    |
| 1 (%)                       | 12 (24%)               | 30 (50.8%)                   | 12 (24%)                    |
| 2 (%)                       | 0                      | 8 (13.6%)                    | 14 (28%)                    |
| 3 (%)                       | 0                      | 0                            | 7 (14%)                     |
| ≥4 (%)                      | 0                      | 1 (1.7%)                     | 0                           |

*Note.* Compared with the control group, *P* < 0.05; **P** < 0.01; ***P** < 0.001.

Compared with the paroxysmal atrial fibrillation group, †*P* < 0.05; ††*P* < 0.01; †††*P* < 0.001.

SBP, systolic blood pressure; DBP, diastolic blood pressure; CAD, coronary atherosclerotic heart disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers.

Univariate analysis, were further analyzed using multiple logistic regression analyses to determine independent predictors. A p-value < 0.05 denoted statistical significance in all analyses.

### 3. Results

#### 3.1. Comparison of Clinical Characteristics between the AF and Control Groups.

There were no statistically significant differences in sex and age among the three groups. In the paroxysmal AF and persistent AF groups, the proportion of patients with high systolic blood pressure, high waist-hip ratio, alcohol history, hypertension, diabetes, coronary heart disease, and hyperlipidemia was significantly increased compared with the control group (Table 1). In addition, the proportion of patients receiving concomitant treatment with antiplatelet therapy, anticoagulation therapy, angiotensin-converting enzyme inhibitors, β-receptor antagonists, and statins was significantly increased (Table 1). Of note, the proportion of patients suffering a stroke in the persistent
AF group was significantly higher than that observed in the paroxysmal AF group (26% versus 5%, respectively, \( P < 0.01 \)).

### Table 2: Comparison of carotid ultrasound indices and VVI indices between the control group and the AF groups (grouped according to the type of AF).

|                         | Control group (n = 50) | Paroxysmal AF group (n = 59) | Persistent AF group (n = 50) |
|-------------------------|------------------------|-----------------------------|-----------------------------|
| Plaque index            | 0.16 ± 0.62            | 1.05 ± 1.33**               | 1.42 ± 1.47***†††           |
| Mean IMT (mm)           | 0.56 ± 0.11            | 0.61 ± 0.10\*               | 0.64 ± 0.13**               |
| Max IMT (mm)            | 0.71 ± 0.13            | 0.77 ± 0.12                 | 0.83 ± 0.15                 |
| Ds (mm)                 | 6.71 ± 0.80            | 7.42 ± 1.14**               | 7.72 ± 1.63**               |
| Dd (mm)                 | 6.24 ± 0.82            | 6.95 ± 1.04**               | 7.22 ± 1.63**               |
| Ep (kPa)                | 751.32 ± 682.21        | 876.08 ± 410.27            | 1091.29 ± 828.84*           |
| Ep\*                    | 9.22 ± 7.68            | 11.42 ± 5.87                | 13.58 ± 12.76*              |
| DC (mmHg·10⁻²)          | 0.15 ± 0.09            | 0.14 ± 0.06                 | 0.14 ± 0.11                 |
| AC (mm²/kPa)            | 1.21 ± 1.23            | 3.35 ± 2.57**               | 3.14 ± 2.76*                |
| \( \beta \)            | 7.35 ± 5.95            | 8.42 ± 3.92                 | 10.34 ± 9.32*               |
| Vs (cm/s)               | 0.56 ± 0.12            | 0.49 ± 0.15\*               | 0.45 ± 0.20**               |
| Vd (cm/s)               | 0.29 ± 0.07            | 0.24 ± 0.07**               | 0.24 ± 0.10**               |
| Vm (cm/s)               | 0.42 ± 0.09            | 0.35 ± 0.14**               | 0.37 ± 0.11\*               |
| Long Ps D (cm/s)        | 0.32 ± 0.19            | 0.21 ± 0.12**               | 0.19 ± 0.13**               |
| Long Ps D (%)           | 5.04 ± 3.63            | 3.28 ± 2.13\*               | 2.67 ± 2.78**               |
| Long Ps D (%)           | 8.74 ± 8.48            | 4.86 ± 2.45**               | 4.10 ± 3.37\*               |
| Long Ps D (%)           | 1.21 ± 1.23            | 0.67 ± 0.39\*               | 0.57 ± 0.49**               |
| Long Ps D (1/s)         | 0.65 ± 0.41            | 0.51 ± 0.28\*               | 0.43 ± 0.31**               |
| Long Ps D (mm)          | 0.27 ± 0.24            | 0.13 ± 0.08**               | 0.13 ± 0.12\*               |
| Long Ps D (mm)          | 0.47 ± 0.53            | 0.21 ± 0.12**               | 0.17 ± 0.15**               |
| tLoD (mm)               | 0.73 ± 0.66            | 0.34 ± 0.17***              | 0.31 ± 0.23***              |
| Ra Pd S (cm/s)          | 0.22 ± 0.17            | 0.19 ± 0.18                 | 0.14 ± 0.14\*               |
| Ra Pd D (cm/s)          | 0.15 ± 0.12            | 0.10 ± 0.05\*               | 0.12 ± 0.11                 |
| Ra Pd S (mm)            | 0.10 ± 0.11            | 0.07 ± 0.06                 | 0.06 ± 0.06\*               |
| Ra Pd D (mm)            | 0.18 ± 0.20            | 0.12 ± 0.08                 | 0.09 ± 0.08\*               |

Note: compared with the control group, \( * P < 0.05; ** P < 0.01; *** P < 0.001 \).

Compared with the paroxysmal atrial fibrillation group, \( * P < 0.05; † P < 0.01; †† P < 0.001 \).

IMT, intima media thickness; VVI, velocity vector imaging; AC, arterial compliance; Ds, systolic diameter; Dd, diastolic diameter; Ep, pressure strain elastic modulus; DC, distensibility coefficient; \( \beta \), stiffness index; Vs, systolic peak velocity; Vd, diastolic peak velocity; Vm, mean velocity; Long Ps D, systolic longitudinal peak velocity; Long Ps S, systolic longitudinal peak strain; Long Ps D, diastolic longitudinal peak strain; Long Ps S, diastolic longitudinal peak strain rate; Long Ps D, diastolic longitudinal peak strain rate; Ra Pd S, systolic radial peak velocity; Ra Pd D, diastolic radial peak velocity; Ra Pd S, systolic radial peak displacement; Ra Pd D, diastolic radial peak displacement; tLoD, total longitudinal displacement.

3.2. Comparison of Carotid Sonography Indices and VVI Indices between the AF and Control Groups (Grouped according to Type of AF). Compared with the control group, in the paroxysmal AF group the mean IMT (0.56 ± 0.11 versus 0.61 ± 0.10, respectively, \( P < 0.05 \)) and arterial compliance (AC) index (1.21 ± 1.23 versus 3.35 ± 2.57, respectively, \( P < 0.001 \)) were significantly increased. The index for blood flow velocity in the carotid was significantly decreased (Table 2).

Compared with the control group, in the persistent AF group the mean IMT (0.56 ± 0.11 versus 0.64 ± 0.13, respectively, \( P < 0.001 \)), AC index (1.21 ± 1.23 versus 3.14 ± 2.76, respectively, \( P < 0.05 \)), and carotid stiffness index (\( \beta \)) (7.35 ± 5.95 versus 10.34 ± 9.32, respectively, \( P < 0.05 \)) were significantly increased, whereas the index for the blood flow velocity in the carotid was significantly decreased (Table 2).

The plaque index (PI) was significantly higher in the persistent AF group than the paroxysmal AF group (1.05 ± 1.33 versus 1.42 ± 1.47, respectively, \( P < 0.001 \)).

For the VVI indices, those reflecting the long-axis longitudinal motion and the long-axis radial motion of the carotid artery were significantly decreased in both AF groups compared with the control group (Table 2). The persistent AF group showed significantly lower tLoD compared with the
control group (0.31 ± 0.23 versus 0.73 ± 0.66, respectively, \( P < 0.0001 \)). This significant decrease in the tLoD index was also observed in the paroxysmal AF group (0.34 ± 0.17 versus 0.73 ± 0.66, respectively, \( P < 0.0001 \)), suggesting that the long-axis motor function of the carotid artery was impaired in patients with AF.

Detailed examples of output derived from the VVI software are shown in Figures 1 and 2. The Figures display longitudinal displacement curves during heart cycles in control subjects and patients with AF.

### Table 3: Comparison of carotid ultrasound indices and VVI indices between the AF groups (grouped according to the CHADS\(_2\) score).

| Index                          | Score = 0 (n=38)   | Score = 1 (n=42)   | Score ≥ 2 (n=29) |
|--------------------------------|--------------------|--------------------|------------------|
| Plaque index                   | 0.78±0.03          | 1.46±1.57          | 1.52±1.48        |
| Mean IMT (mm)                  | 0.60±0.12          | 0.62±0.10          | 0.67±0.10\*     |
| Max IMT (mm)                   | 0.75±0.14          | 0.80±0.12          | 0.86±0.14\*     |
| Ds (cm)                        | 0.72±0.17          | 0.77±0.11          | 0.77±0.11        |
| Dd (cm)                        | 0.68±0.17          | 0.72±0.10          | 0.71±0.10        |
| Ep (kPa)                       | 887.81±854.52      | 1027.38±441.45     | 1017.86±574.22  |
| LongPdD(mm)                    | 0.17±0.09          | 0.12±0.06          | 0.16±0.14        |
| AC (mm2/kPa)                   | 2.19±0.95          | 3.84±3.02\*       | 3.80±3.19\*     |
| \( \beta \)                    | 9.26±10.21         | 9.39±4.14          | 9.25±4.93       |
| Vs (cm/s)                      | 0.51±0.16          | 0.48±0.19          | 0.42±0.15\*     |
| Vd (cm/s)                      | 0.26±0.10          | 0.23±0.09          | 0.21±0.08\*     |
| Vm (cm/s)                      | 0.39±0.11          | 0.35±0.13          | 0.32±0.11\*     |
| RI                             | 0.48±0.07          | 0.51±0.11          | 0.48±0.12       |
| PI                             | 0.63±0.12          | 0.60±0.21          | 0.65±0.21       |
| Long Ps S (cm/s)               | 0.25±0.17          | 0.31±0.21          | 0.25±0.19       |
| Long Ps D (cm/s)               | 0.18±0.10          | 0.21±0.13          | 0.22±0.14       |
| Long Ps S (%)                  | 2.58±1.86          | 3.65±2.74          | 2.62±2.58       |
| Long Ps D (%)                  | 3.94±2.21          | 5.05±3.19          | 4.49±3.25       |
| Long Psr S (1/s)               | 0.57±0.34          | 0.72±0.47          | 0.58±0.50       |
| Long Psr D (1/s)               | 0.43±0.25          | 0.52±0.32          | 0.47±0.32       |
| Long Pd S (mm)                 | 0.10±0.09          | 0.14±0.09          | 0.16±0.13\*     |
| Long Pd D (mm)                 | 0.17±0.12          | 0.23±0.16          | 0.16±0.10       |
| tLoD (mm)                      | 0.27±0.17          | 0.38±0.21          | 0.32±0.20       |
| Ra Ps S (cm/s)                 | 0.17±0.16          | 0.19±0.19          | 0.13±0.12       |
| Ra Ps D (cm/s)                 | 0.10±0.08          | 0.10±0.06          | 0.13±0.12       |
| Ra Ps S (mm)                   | 0.05±0.04          | 0.07±0.06          | 0.07±0.06       |
| Ra Ps D (mm)                   | 0.11±0.09          | 0.11±0.08          | 0.10±0.08       |

Note: compared with the low-risk group (score = 0), \(* P < 0.05; ** P < 0.01; *** P < 0.001\). IMT, intima media thickness; VVI, velocity vector imaging; AC, arterial compliance; Ds, systolic diameter; Dd, diastolic diameter; Ep, pressure strain modulus; DC, distensibility coefficient; \( \beta \), stiffness index; Vs, systolic peak velocity; Vd, diastolic peak velocity; Vm, mean velocity; Long Ps, systolic longitudinal peak velocity; Long Ps D, diastolic longitudinal peak velocity; Long Ps S, systolic longitudinal peak strain; Long Ps D, diastolic longitudinal peak strain; Long Psr S, systolic longitudinal peak strain rate; Long Psr D, diastolic longitudinal peak strain rate; Long Pd S, systolic longitudinal peak displacement; Long Pd D, diastolic longitudinal peak displacement; Ra Ps, systolic radial peak velocity; Ra Ps D, diastolic radial peak velocity; Ra Ps S, systolic radial peak displacement; Ra Ps D, diastolic radial peak displacement; tLoD, total longitudinal displacement.

3.3. Comparison of Carotid Ultrasound Indices and VVI Indices between Patients (Grouped according to the CHADS\(_2\) Score). Compared with the low-risk group (CHADS\(_2\) scores of 0), in the high-risk group (CHADS\(_2\) scores >2) the mean IMT (0.60 ± 0.12 versus 0.67 ± 0.10, respectively, \( P < 0.05 \)), maximum IMT (0.75 ± 0.14 versus 0.86 ± 0.14, respectively, \( P < 0.01 \)), and AC index (2.19 ± 0.95 versus 3.80 ± 3.19, respectively, \( P < 0.05 \)) were significantly increased (Table 3). However, the index for blood flow velocity was significantly decreased (Table 3). The PI showed a tendency to increase, without reaching statistical significance. There were no statistically significant differences in these indices between the moderate-risk and high-risk groups.

3.4. Correlation Analysis between the CHADS\(_2\) Score, Carotid Sonography, and VVI Indices in the AF Groups. In patients with AF, the CHADS\(_2\) score was linked to indicators reflecting...
the structure of the carotid artery, including PI (r = 0.297, P = 0.002), mean IMT (r = 0.272, P < 0.001), and maximum IMT (r = 0.337, P < 0.001). Moreover, it correlated with indices reflecting carotid function (Table 4). Correlation analysis using the VVI indices showed that the CHADS<sub>2</sub> score was correlated with indicators reflecting the long-axis longitudinal motion of the carotid artery (Table 4).

3.5. Logistic Regression to Identify Risk Factors for IMT Thickening (Table 5). The CHADS<sub>2</sub> score, total cholesterol, and LDL cholesterol were entered into the multivariate logistic regression analysis. The results showed that individuals with a high CHADS<sub>2</sub> score [odds ratio (OR): 1.676, 95% confidence interval (CI): 1.075–2.661, P = 0.023], increased total cholesterol (OR: 0.225, 95% CI: 0.085–0.596, P = 0.003), and increased LDL cholesterol (OR: 14.526, 95% CI: 3.329–63.385, P < 0.001) were susceptible to IMT thickening.

4. Discussion

Clinical evidence has suggested that atherosclerosis and AF may be correlated and mutually promoted [20–22]. Patients with concurrent AF and atherosclerosis have a higher mortality rate compared with those diagnosed with either AF or atherosclerosis [23]. Studies have shown that the risk of developing AF is higher in patients with carotid atherosclerosis [21–23]. Other studies have also shown that AF itself may accelerate the occurrence and development of coronary atherosclerosis and myocardial infarction [20, 22].

Atherosclerotic plaques develop mainly in sites of frequent hemodynamic changes such as arterial bifurcations, openings, or curving. This suggests that abnormalities in hemodynamics play a major role in the development of atherosclerosis. In 1997, Minamino et al. [24] proposed that the abnormality in hemodynamics caused by AF was in part responsible for endothelial dysfunction and that endothelial injury was the initiating factor for atherosclerosis. Pober and Cotran proposed the shear stress hypothesis [25], suggesting that laminar flow shear stress may selectively induce the blood vessel endothelium to express "protective factors of atherosclerosis." However, in cases of abnormal blood flow shear stress, this expression of protective factors invascular endothelial cells is decreased or ceased. Therefore, the function of antiatherosclerosis would be inaccessible. Endothelial injury is the basis for the occurrence of atherosclerotic plaques.

Carotid arteries are useful for the observation of systemic atherosclerosis. Therefore, in the present study, high-resolution color Doppler ultrasound was used to evaluate the vascular structure and function of carotid arteries in patients with AF. The results indicated significant changes in carotid artery structure for patients with AF and a significant increase in the incidence and deterioration of atherosclerosis. At the same time, several indicators of carotid hemodynamics were altered, indicating decreased elasticity and increased stiffness in patients with AF. The PI of carotid arteries in patients with persistent AF were significantly greater than those in patients with paroxysmal AF. This finding indicated that the development of atherosclerosis is dependent on the duration of AF [26, 27]. In our study, the data demonstrate that the systolic blood pressure was higher in both paroxysmal and persistent AF groups than in the control group. Hypertension
is an important risk factor for arterial stiffness [28] and also for atrial fibrillation [6]. Studies [29, 30] and animal models of genetic or experimental hypertension [31–33] suggest hypertension exerts a direct effect on the cardiovascular system, stimulates hyperplasia and hypertrophy of vascular smooth muscle cells and adventitial cell migration, and may therefore lead to notable pathophysiological consequences, such as interfering with vessel mechanical properties. Therefore, the increased carotid stiffness in patients with atrial fibrillation in our study was also influenced by hypertension. Hypertension aggravates the hemodynamic changes in patients with atrial fibrillation, thereby promoting the structural changes and further reducing the function of the carotid artery.

Furthermore, VVI was used to observe and compare motion characteristics of the long axis of the CCA in patients with AF and controls. The results demonstrated long-axis motor dysfunction of the CCA in patients with AF. During VVI, patients traced in the two-dimensional image are tracked automatically in real time. Changes and intervals of pixels on each successive frame of the image are tracked and compared, thus displaying the true motion speed and displacement of the tissue in a vector manner and showing the indicators in curves. In this way, quantitative analysis for structural mechanics of the patients is possible in multiple planes and at various phases [19, 34]. Svedlund et al. used VVI to evaluate the long-axis motion of the CCA and found that the anterior and posterior walls of CCA in controls showed similar motion tendency. In contrast, the motion of the long axis of the CCA in patients with coronary atherosclerotic heart disease was significantly weaker than that observed in controls [17]. Therefore, VVI may be used to visually observe characteristic variations in the structural mechanics of the vascular endothelium and evaluate the elasticity of vascular walls [18, 19, 34].

The correlation between the CHADS2 score and carotid artery ultrasound indicators was investigated to estimate the degree and risk for the development of carotid atherosclerosis. The results showed that the CHADS2 score was correlated with multiple ultrasound indicators reflecting the structure and function of the carotid artery. The degree of carotid atherosclerosis in patients with a high CHADS2 score (≥2) was significantly higher than that observed in patients with a low-risk score (0). Therefore, the CHADS2 score is able to also predict the degree of carotid atherosclerosis in patients with nonvalvular AF. The increase in the score is accompanied with impaired structure and dysfunction of the carotid artery. This assessment method is simple and feasible, prompting physicians to determine the need for administration of statins.
Table 4: Correlation analysis of CHADS$^2$ score, carotid ultrasound, and VVI indices.

|                       | CHADS$^2$ score |        |
|-----------------------|-----------------|--------|
| Plaque index          | 0.297           | 0.002  |
| Mean IMT (mm)         | 0.272           | <0.001 |
| Max IMT (mm)          | 0.337           | <0.001 |
| Ds (cm)               | 0.345           | <0.001 |
| Dd (cm)               | 0.346           | <0.001 |
| Ep (kPa)              | 0.334           | 0.001  |
| $Ep^*$                | 0.278           | 0.001  |
| DC (mmH$^{-1} \times 10^{-3}$) | −0.157        | 0.047  |
| AC (mm2/kPa)          | 0.252           | 0.001  |
| $\beta$              | 0.259           | 0.001  |
| Vs (cm/s)             | −0.315          | <0.001 |
| Vd (cm/s)             | −0.342          | <0.001 |
| Vm (cm/s)             | −0.288          | 0.003  |
| Long Pv S (cm/s)      | −0.196          | 0.013  |
| Long Pv D (cm/s)      | −0.102          | 0.203  |
| Long Ps (\%)         | −0.134          | 0.092  |
| Long Ps D (\%)       | −0.166          | 0.037  |
| Long Psr S (1/s)      | −0.191          | 0.016  |
| Long Psr D (1/s)      | −0.100          | 0.210  |
| Long Pd S (mm)        | −0.065          | 0.416  |
| Long Pd D (mm)        | −0.215          | 0.007  |
| tLoD (mm)             | −0.19           | 0.017  |
| Ra Pv S (cm/s)        | −0.127          | 0.112  |
| Ra Pd D (cm/s)        | 0.012           | 0.884  |
| Ra Pd S (mm)          | 0.023           | 0.77   |
| Ra Pd D (mm)          | −0.134          | 0.093  |

IMT, intima media thickness; VVI, velocity vector imaging; AC, arterial compliance; Ds, systolic diameter; Dd, diastolic diameter; Ep, pressure strain elastic modulus; DC, distensibility coefficient; Vs, systolic peak velocity; Vd, diastolic peak velocity; Vm, mean velocity; Long Pv S, systolic longitudinal peak velocity; Long Pv D, diastolic longitudinal peak velocity; Long Ps S, systolic longitudinal peak strain; Long Ps D, diastolic longitudinal peak strain; Long Psr S, systolic longitudinal peak strain rate; Long Psr D, diastolic longitudinal peak strain rate; Long Pd S, systolic longitudinal peak displacement; Long Pd D, diastolic longitudinal peak displacement; tLoD, total longitudinal displacement.

Table 5: Logistic regression to identify risk factors for IMT thickening.

|                | $\beta$ | $P$   | OR    | 95% CI    |
|----------------|---------|-------|-------|-----------|
| CHADS$^2$ score | 0.516   | 0.023 | 1.676 | 1.075–2.661 |
| Cholesterol (mmol/L) | −1.491 | 0.003 | 0.225 | 0.085–0.596 |
| LDL cholesterol (mmol/L) | 2.676 | <0.001 | 14.526 | 3.329–63.385 |

in patients with a high CHADS$^2$ score. This approach may alleviate the progression of atherosclerosis and reduce the risk of stroke.

5. Conclusions

The carotid arterial structure and function in patients with AF were significantly changed, including increased arterial wall stiffness, decreased elasticity, and aggravated atherosclerosis. A positive correlation between the CHADS$^2$ score and carotid ultrasound indicators was found, indicating that risk stratification of AF stroke may also reflect the degree of structural and functional impairment of the carotid artery. Consequently, this may contribute to the assessment of the degree of carotid atherosclerosis.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors have no conflicts of interest to declare.
Authors’ Contributions
Le-yu Lin and Lian-wei Yang contributed equally to this study.

Acknowledgments
The authors thank all clinical research coordinators for their assistance in obtaining informed consent and collecting the clinical data. This work was supported by research grants from the National Natural Science Foundation of China (81470560, 81570400, 81670411, and 81471036), the Key Research and Development Program of Shandong Province (2017GSF18156, 2018GSF118017, and 2018GSF118002), and the Natural Science Foundation of Shandong Province (Y2005C61, ZR2014HQ037, and ZR2017BH023).

References
[1] P. A. Wolf, R. D. Abbott, and W. B. Kannel, “Atrial fibrillation as an independent risk factor for stroke: the Framingham study,” *Stroke*, vol. 22, no. 8, pp. 983–988, 1991.

[2] M. F. Stoddard, P. R. Dawks, C. R. Prince, and N. M. Ammass, “Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: A transesophageal echocardiographic study,” *Journal of the American College of Cardiology*, vol. 25, no. 2, pp. 452–459, 1995.

[3] K. Willeit and S. Kiechl, “Atherosclerosis and atrial fibrillation - Two closely intertwined diseases,” *Atherosclerosis*, vol. 233, no. 2, pp. 679–681, 2014.

[4] L. Y. Chen, D. C. Foo, R. C. Wong et al., “Increased carotid intima-media thickness and arterial stiffness are associated with lone atrial fibrillation,” *International Journal of Cardiology*, vol. 168, no. 3, pp. 3132–3134, 2013.

[5] H. Lehtola, K. E. I. Airaksinen, P. Hartikainen et al., “Stroke recurrence in patients with atrial fibrillation: concomitant carotid artery stenosis doubles the risk,” *European Journal of Neurology*, vol. 24, no. 5, pp. 719–725, 2017.

[6] V. Fuster, L. E. Ryden, D. S. Cannom et al., “Acc/aha/esc 2006 guidelines for the management of patients with atrial fibrillation: a report of the american college of cardiology/american heart association task force on practice guidelines and the european society of cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the european heart rhythm association and the heart rhythm society,” *Circulation*, vol. 114, no. 7, pp. e257–e354, 2006.

[7] S. Puwanant, B. C. Varr, K. Shrestha et al., “Role of the CHADS2 score in the evaluation of thromboembolic risk in patients with atrial fibrillation undergoing transesophageal echocardiography before pulmonary vein isolation,” *Journal of the American College of Cardiology*, vol. 54, no. 22, pp. 2032–2039, 2009.

[8] S. K. Saha, P. L. Anderson, G. Caracciolo et al., “Global left atrial strain correlates with CHADS2 risk score in patients with atrial fibrillation,” *Journal of the American Society of Echocardiography*, vol. 24, no. 5, pp. 506–512, 2011.

[9] I. K. Ekroll, T. Dahl, H. Torp, and L. Levstakken, “Combined vector velocity and spectral doppler imaging for improved imaging of complex blood flow in the carotid arteries,” *Ultrasound in Medicine & Biology*, vol. 40, no. 7, pp. 1629–1640, 2014.

[10] P. Tortoli, M. Lenge, D. Right, G. Ciuti, H. Liebgott, and S. Ricci, “Comparison of carotid artery blood velocity measurements by vector and standard doppler approaches,” *Ultrasound in Medicine & Biology*, vol. 41, no. 5, pp. 1354–1362, 2015.

[11] N. A. M. Estes III, J. L. Halperin, H. Calkins et al., “ACC/AHA/Physician consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: A report of the American college of cardiology/American heart association task force on performance measures and the physician consortium for performance improvement (writing committee to develop clinical performance measures for atrial fibrillation),” *Circulation*, vol. 117, no. 8, pp. 1101–1120, 2008.

[12] V. Fuster, L. E. Ryden, D. S. Cannom et al., “2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society,” *Journal of the American College of Cardiology*, vol. 57, no. 11, pp. e901–e988, 2011.

[13] M. Rizzo, M. Chandalia, A. M. Patti et al., “Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study,” *Cardiovascular Diabetology*, vol. 13, no. 1, article no. 49, 2014.

[14] K. N. Thomas, N. C. Lewis, B. G. Hill, and P. N. Ainslie, “Technical recommendations for the use of carotid duplex ultrasound for the assessment of extracranial blood flow,” *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology*, vol. 309, no. 7, pp. R707–R720, 2015.

[15] G. Kerekes, P. Soltész, M. T. Nurnmohamed et al., “Validated methods for assessment of subclinical atherosclerosis in rheumatology,” *Nature Reviews Rheumatology*, vol. 8, no. 4, pp. 224–234, 2012.

[16] S. Svedlund and L.-M. Gan, “Longitudinal wall motion of the common carotid artery can be assessed by velocity vector imaging,” *Clinical Physiology and Functional Imaging*, vol. 31, no. 1, pp. 32–38, 2011.

[17] M. Cinthio, A. R. Ahlgren, J. Bergkvist, T. Jansson, H. W. Persson, and K. Lindström, “Longitudinal movements and resulting shear strain of the arterial wall,” *American Journal of Physiology-Heart and Circulatory Physiology*, vol. 291, no. 1, pp. H394–H402, 2006.

[18] L. N. Bohs, B. J. Geiman, M. E. Anderson, S. C. Gebhart, and G. E. Trahey, “Speckle tracking for multi-dimensional flow estimation,” *Ultrasonics*, vol. 38, no. 1, pp. 369–375, 2000.

[19] J. Heeringa, D. A. M. Van Der Kuip, A. Hofman et al., “Subclinical atherosclerosis and risk of atrial fibrillation: The Rotterdam study,” *JAMA Internal Medicine*, vol. 167, no. 4, pp. 382–387, 2007.

[20] E. J. Benjamin, D. Levy, S. M. Vaziri, R. B. D’Agostino, A. J. Belanger, and P. A. Wolf, “Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham heart study,” *Journal of the American Medical Association*, vol. 271, no. 11, pp. 840–844, 1994.

[21] E. Jover, F. Marin, V. Roldán, S. Montoro-García, M. Valdés, and G. Y. H. Lip, “Atherosclerosis and thromboembolic risk in...
atrial fibrillation: Focus on peripheral vascular disease,” *Annals of Medicine*, vol. 45, no. 3, pp. 274–290, 2013.

[23] K. Willeit, R. Pechlaner, G. Egger et al., “Carotid atherosclerosis and incident atrial fibrillation,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 33, no. 11, pp. 2660–2665, 2013.

[24] T. Minamino, M. Kitakaze, H. Sate et al., “Plasma levels of nitrite/nitrate and platelet cGMP levels are decreased in patients with atrial fibrillation,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 17, no. 11, pp. 3191–3195, 1997.

[25] J. S. Pober and R. S. Cotran, “Cytokines and endothelial cell biology,” *Physiological Reviews*, vol. 70, no. 2, pp. 427–451, 1990.

[26] A. D. Krahn, J. Manfreda, R. B. Tate, F. A. L. Mathewson, and T. E. Cuddy, “The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the manitoba follow-up study,” *American Journal of Medicine*, vol. 98, no. 5, pp. 476–484, 1995.

[27] S. Adamsson Eryd, G. Östling, M. Rosvall et al., “Carotid intima-media thickness is associated with incidence of hospitalized atrial fibrillation,” *Atherosclerosis*, vol. 233, no. 2, pp. 673–678, 2014.

[28] G. Bernini, F. Galetta, F. Franzoni et al., “Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism,” *Journal of Hypertension*, vol. 26, no. 12, pp. 2399–2405, 2008.

[29] A. Mano, T. Tatsumi, J. Shiraishi et al., “Aldosterone directly induces myocyte apoptosis through calcineurin-dependent pathways,” *Circulation*, vol. 110, no. 23, pp. 317–323, 2004.

[30] P. Lijnen and V. Petrov, “Induction of cardiac fibrosis by aldosterone,” *Journal of Molecular and Cellular Cardiology*, vol. 32, no. 6, pp. 865–879, 2000.

[31] A. K. Burla, M. F. Neves, W. Oigman, and C. A. Mandarim-de-Lacerda, “Eplerenone offsets cardiac and aortic adverse remodeling in spontaneously hypertensive rats,” *International Journal of Cardiology*, vol. 114, no. 1, pp. 64–70, 2007.

[32] J. G. Burniston, A. Saini, L.-B. Tan, and D. F. Goldspink, “Aldosterone induces myocyte apoptosis in the heart and skeletal muscles of rats in vivo,” *Journal of Molecular and Cellular Cardiology*, vol. 39, no. 2, pp. 395–399, 2005.

[33] A. J. Rickard, J. W. Funder, P. J. Fuller, and M. J. Young, “The role of the glucocorticoid receptor in mineralocorticoid/salt-mediated cardiac fibrosis,” *Endocrinology*, vol. 147, no. 12, pp. 5901–5906, 2006.

[34] Q. Wang, Y. Q. Qian, and L. W. Liu, “Velocity vector imaging evaluation of common carotid arterial wall motion in cerebral infraction patients: preliminary study,” *Chinese Journal of Ultrasound in Medicine*, vol. 23, pp. 1831–1833, 2007.